PTC Therapeutics, Inc. (NASDAQ: PTCT) announced Friday that the Food and Drug Administration approved a label expansion for the drug Emflaza to include younger patients with Duchenne muscular dystrophy who are between 2 and 5 years old.
PTC Therapeutics shares were trading higher by 2.73 percent to $41.40 at the time of publication Friday.
Duchenne muscular dystrophy is a rare childhood genetic disorder that causes progressive, irreversible muscle deterioration and weakness.
Duchenne is a severe type of muscular dystrophy, and symptoms of muscle weakness usually begin around the age of 4 in boys and worsen quickly; females with a single copy of the defective gene may show mild symptoms.
Emflaza was first approved by the FDA in February 2017 for the treatment of Duchenne in patients 5 and older.
"We are excited to be able to bring Emflaza to younger boys living with Duchenne muscular dystrophy," PTC Therapeutics CEO Stuart Peltz said in a statement.
"The standard of care is to start Emflaza at the time of diagnosis. We believe that treating patients as young as possible, when they still have a substantial amount of muscle, will have the greatest benefit for patients that are two years and older."
US Adds 75,000 Jobs In May, Far Below Estimates
A Peek Into The Markets: US Stock Futures Surge; All Eyes On Jobs Report
See more from Benzinga
- FedEx Express Drops Amazon, Focuses On 'Broader E-Commerce Market'
- Baker Hughes Reports Climb In Total Oil Rigs
- Report: Huawei Looks Outside US For Solar Parts
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.